Also found in: Medical, Wikipedia.
CD44Cluster of Differentiation 44
References in periodicals archive ?
About the OncAlert Oral Cancer Risk Assessment System Vigilant's initial product, the OncAlert Oral Cancer Risk Assessment System, includes the OncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test and the OncAlert Oral Cancer CD44 + Total Protein Lab Test.
The poster presentation, entitled, "6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies," covers pre-clinical work completed by Bio-Quant on ngstrom's lead product, 6, currently in Phase 2 development for ovarian cancer.
Uromodulin, SERPINF1 (serpin peptidase inhibitor, clade F, [alpha]-2 antiplasmin, pigment epithelium derived factor, member 1), and CD44 were verified in an independent cohort and shown to differentiate patients with AR from other groups.
Poster #4293: Evaluation of activated CD44 as a biological target in the eradication of breast cancer stem cells
Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
Our preliminary data strongly suggests that vitamin D suppression of HAS2 activity and HA synthesis represents a feasible approach for interrupting the CD44 signaling process in TNBC cells.
The expression of CSC markers such as CD44, CD24, and ALDH1 has also been shown in CTCs by both molecular assays (42) and imaging (73).
The major genes that have been shown to be epigenetically altered in prostate cancers include cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), cadherin 1, type 1, E-cadherin (epithelial) (CDH1), CD44 molecule (Indian blood group) (CD44), O-6-methylguanine-DNAmethyltransferase (MGMT), Ras association (RalGDS/AF-6) domain family member 1 (RASSF1A), ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), adenomatous polyposis coli (APC), and glutathione S-transferase pi 1 (GSTP1).
The wide array of molecular-based PCa markers includes proliferation index (Ki-67), microvessel density, nuclear morphometry, tumor suppressor genes (eg, TP53, CDKN1A, CDKN1B, NKX3-1, PTEN, and the retinoblastoma gene Rb), oncogenes (eg, BCL2, MYC, EZH2, and ERBB2 [formerly HER2/neu]), adhesion molecules (eg, CD44 and E-cadherin), the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, (30,31) apoptosis regulators (eg, survivin and transforming growth factor p1), androgen receptor status, neuroendocrine differentiation markers, and prostate tissue lineage-specific markers (PSA, prostate-specific acid phosphatase, and prostate-specific membrane antigen).
EPR subjects with functional SNPs in CD44 (receptor for hyaluronic acid) and I [alpha]I (inter-[alpha]-inhibitor) will be exposed to ozone via inhalation and examined for bronchoconstrictive responses to inhaled methacholine.